Trabectedin in Soft Tissue Sarcoma: Have We Hit the Bull's-eye?

Affiliations

Comment

Sameer Rastogi et al. J Clin Oncol. 2016.

. 2016 Oct 10;34(29):3582-3583.

doi: 10.1200/JCO.2015.65.7130.

No abstract available

Comment in

Reply to S. Rastogi et al.
Demetri GD. Demetri GD. J Clin Oncol. 2016 Oct 10;34(29):3583. doi: 10.1200/JCO.2016.68.3029. J Clin Oncol. 2016. PMID: 27458282 No abstract available.
Reply to S. Rastogi et al.
Schwartz GK. Schwartz GK. J Clin Oncol. 2016 Oct 10;34(29):3584. doi: 10.1200/JCO.2016.68.3037. J Clin Oncol. 2016. PMID: 27458303 No abstract available.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Demetri GD, et al. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14. J Clin Oncol. 2016. PMID: 26371143 Free PMC article. Clinical Trial.